JP7041519B2 - Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 - Google Patents

Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 Download PDF

Info

Publication number
JP7041519B2
JP7041519B2 JP2017566768A JP2017566768A JP7041519B2 JP 7041519 B2 JP7041519 B2 JP 7041519B2 JP 2017566768 A JP2017566768 A JP 2017566768A JP 2017566768 A JP2017566768 A JP 2017566768A JP 7041519 B2 JP7041519 B2 JP 7041519B2
Authority
JP
Japan
Prior art keywords
antibody
seq
pharmaceutical composition
cells
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017566768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527299A (ja
Inventor
アフマディ，タハムタン
カズナフ，タイネク
エム． ロクホースト，ヘンク
マティス，ツナ
サセール，エイミー
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2018527299A publication Critical patent/JP2018527299A/ja
Priority to JP2022015442A priority Critical patent/JP7532428B2/ja
Application granted granted Critical
Publication of JP7041519B2 publication Critical patent/JP7041519B2/ja
Priority to JP2024123110A priority patent/JP2024153803A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017566768A 2015-06-24 2016-06-24 Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療 Active JP7041519B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022015442A JP7532428B2 (ja) 2015-06-24 2022-02-03 Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療
JP2024123110A JP2024153803A (ja) 2015-06-24 2024-07-30 Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562184018P 2015-06-24 2015-06-24
US62/184,018 2015-06-24
US201562249546P 2015-11-02 2015-11-02
US62/249,546 2015-11-02
US201562250566P 2015-11-04 2015-11-04
US62/250,566 2015-11-04
US201562263307P 2015-12-04 2015-12-04
US62/263,307 2015-12-04
US201662331489P 2016-05-04 2016-05-04
US62/331,489 2016-05-04
PCT/US2016/039165 WO2016210223A1 (en) 2015-06-24 2016-06-24 Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022015442A Division JP7532428B2 (ja) 2015-06-24 2022-02-03 Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療

Publications (2)

Publication Number Publication Date
JP2018527299A JP2018527299A (ja) 2018-09-20
JP7041519B2 true JP7041519B2 (ja) 2022-03-24

Family

ID=57586547

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017566768A Active JP7041519B2 (ja) 2015-06-24 2016-06-24 Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療
JP2022015442A Active JP7532428B2 (ja) 2015-06-24 2022-02-03 Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療
JP2024123110A Pending JP2024153803A (ja) 2015-06-24 2024-07-30 Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022015442A Active JP7532428B2 (ja) 2015-06-24 2022-02-03 Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療
JP2024123110A Pending JP2024153803A (ja) 2015-06-24 2024-07-30 Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療

Country Status (37)

Country Link
US (1) US20160376373A1 (enExample)
EP (2) EP3313441B1 (enExample)
JP (3) JP7041519B2 (enExample)
KR (2) KR102713847B1 (enExample)
CN (1) CN107921120A (enExample)
AU (1) AU2016281717B2 (enExample)
BR (1) BR112017027990A2 (enExample)
CA (1) CA2990620A1 (enExample)
CL (2) CL2017003275A1 (enExample)
CO (1) CO2017013332A2 (enExample)
DK (1) DK3313441T5 (enExample)
DO (1) DOP2017000305A (enExample)
EA (1) EA037548B1 (enExample)
EC (1) ECSP17084878A (enExample)
ES (1) ES2982292T3 (enExample)
FI (1) FI3313441T3 (enExample)
GT (1) GT201700286A (enExample)
HR (1) HRP20240338T1 (enExample)
HU (1) HUE066300T2 (enExample)
IL (1) IL256248A (enExample)
LT (1) LT3313441T (enExample)
MA (1) MA71262A (enExample)
MD (1) MD3313441T2 (enExample)
MX (3) MX2018000261A (enExample)
MY (1) MY193727A (enExample)
NI (1) NI201700170A (enExample)
PE (1) PE20181090A1 (enExample)
PH (1) PH12017502311A1 (enExample)
PL (1) PL3313441T3 (enExample)
PT (1) PT3313441T (enExample)
RS (1) RS65347B1 (enExample)
SI (1) SI3313441T1 (enExample)
SM (1) SMT202400127T1 (enExample)
SV (1) SV2017005607A (enExample)
UA (1) UA124799C2 (enExample)
WO (1) WO2016210223A1 (enExample)
ZA (1) ZA201800476B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037929B1 (ru) * 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PL3122173T5 (pl) 2014-03-26 2024-08-05 Scr Engineers Ltd System lokalizacji żywego inwentarza
EP3122781B1 (en) 2014-03-28 2020-01-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US10986817B2 (en) 2014-09-05 2021-04-27 Intervet Inc. Method and system for tracking health in animal populations
US11071279B2 (en) 2014-09-05 2021-07-27 Intervet Inc. Method and system for tracking health in animal populations
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
WO2016089960A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
MA42136A (fr) 2015-05-20 2018-03-28 Janssen Biotech Inc Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
BR112018008891A8 (pt) * 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
PH12018500950B1 (en) 2015-11-03 2023-09-20 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
WO2017100372A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
KR20230091191A (ko) 2016-05-27 2023-06-22 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
IL267886B2 (en) * 2017-01-09 2024-11-01 Biomunex Pharmaceuticals A polypeptide linker for preparing multispecific antibodies
BR112019015355A2 (pt) * 2017-01-26 2020-05-19 Sangamo Therapeutics Inc modificação genética de células b
KR20250025513A (ko) * 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
CN111051344B (zh) 2017-06-08 2023-10-27 黑带医疗有限公司 Cd38调节抗体
KR20250025514A (ko) 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
AU2018316522B2 (en) 2017-08-16 2025-02-20 Black Belt Therapeutics Limited CD38 antibody
AU2018316521B2 (en) 2017-08-16 2025-01-30 Black Belt Therapeutics Limited CD38 modulating antibody
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
US11832584B2 (en) 2018-04-22 2023-12-05 Vence, Corp. Livestock management system and method
JP7534281B2 (ja) * 2018-07-13 2024-08-14 ジェンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
MY205398A (en) 2018-07-13 2024-10-19 Genmab As Variants of cd38 antibody and uses thereof
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
WO2020069439A1 (en) * 2018-09-27 2020-04-02 Musc Foundation For Research Development Pharmaceutical combination for the treatment of cancer
FR3086837B1 (fr) 2018-10-03 2021-06-18 Allflex Europe Pince pour la manipulation d’un dispositif d’identification d’un animal et/ou de prelevement d’un tissu d’un animal comprenant des moyens de maintien a moyens d’actionnement deportes
CN112911927B (zh) 2018-10-10 2023-06-27 世亚工程设备有限公司 牲畜干乳方法和装置
CA3129171A1 (en) 2019-02-08 2020-08-13 Allflex Australia Pty Ltd Electronic animal tag reader
US12144320B2 (en) 2019-02-08 2024-11-19 Allflex Australia Pty Ltd Electronic animal identification tag reader synchronisation
WO2020160588A1 (en) 2019-02-08 2020-08-13 Allflex Australia Pty Ltd Determining the location of an animal
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
AU2020335853A1 (en) 2019-08-28 2022-04-14 S.C.R. (Engineers) Limited Devices for analysis of a fluid
KR20220130724A (ko) 2020-01-16 2022-09-27 젠맵 에이/에스 Cd38 항체의 제제 및 그의 용도
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
USD990063S1 (en) 2020-06-18 2023-06-20 S.C.R. (Engineers) Limited Animal ear tag
USD990062S1 (en) 2020-06-18 2023-06-20 S.C.R. (Engineers) Limited Animal ear tag
IL275518B (en) 2020-06-18 2021-10-31 Scr Eng Ltd Animal tag
IL275812B (en) 2020-07-01 2022-01-01 Scr Eng Ltd System and method for placing devices
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
IL302630A (en) 2020-11-25 2023-07-01 Identigen Ltd A system and method for tracking members of an animal population
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
TW202235435A (zh) 2021-01-14 2022-09-16 德商莫菲西斯公司 抗cd38抗體及其用途
IL280374B2 (en) 2021-01-24 2023-11-01 Scr Eng Ltd System and method for controlling animal marking
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
CA206747S (en) 2021-04-08 2024-12-30 Chevillot Sas Tag applicator for animals
CA206812S (en) 2021-04-08 2023-04-11 Chevillot Sas Tag applicator for animals
US20240392000A1 (en) * 2021-08-25 2024-11-28 Biograph 55, Inc. Methods of treating cancers associated with immunosuppressive b cells
US20230330138A1 (en) * 2022-04-14 2023-10-19 Creative Medical Technologies, Inc. Treatment of cartilage degeneration using myeloid suppressor cells and exosomes derived thereof
US12402596B2 (en) 2022-05-03 2025-09-02 S.C.R. (Engineers) Limited Milk channel and feed inlet coupled thereto, and system and method for conserving wash fluid in a washing process for cleaning a milkmeter system
CN114805582B (zh) * 2022-06-29 2022-10-04 上海恒润达生生物科技股份有限公司 抗Trop2纳米抗体及其用途
EP4612177A1 (en) 2022-10-31 2025-09-10 Genmab A/S Cd38 antibodies and uses thereof
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533977A (ja) 2005-03-23 2008-08-28 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
JP2013539352A (ja) 2010-06-09 2013-10-24 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2564103T3 (es) 2003-03-05 2016-03-17 Halozyme, Inc. Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
HUE035250T2 (hu) 2005-10-12 2018-05-02 Morphosys Ag Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2008073160A2 (en) * 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
ME03503B (me) * 2006-09-26 2020-04-20 Genmab As Anti-cd38 plus kortkosteroidni plus ne-kortikosteroidni hemoterapeutik za tretiranje tumora
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
CA2710373A1 (en) 2007-12-19 2009-07-09 Ping Tsui Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP2899209A1 (en) 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US9179480B2 (en) 2012-07-24 2015-11-03 Telefonaktiebolaget L M Ericsson (Publ) Apparatus and method for dynamically selecting a random access response window value for use with random access procedures in a network
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2914302B1 (en) * 2012-11-05 2017-01-04 MorphoSys AG Radiolabelled antibody and uses thereof
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US20140356318A1 (en) * 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
US20160235842A1 (en) * 2013-07-15 2016-08-18 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists
JP2016536361A (ja) * 2013-11-06 2016-11-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP7382695B2 (ja) * 2020-07-09 2023-11-17 パーカーエンジニアリング株式会社 塗料ミスト捕集装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533977A (ja) 2005-03-23 2008-08-28 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
JP2013539352A (ja) 2010-06-09 2013-10-24 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Data show daratumumab achieved a pronounced overall response rate as a single-agent with tolerable safety profile in heavily pre-treated multiple myeloma patients，Johnson & Johnson Press release[online](retrived on 2020 Jul 27)，2015年05月30日，retrieved from the Internet<URL:https://www.jnj.com/media-center/press-releases/Data-show-daratumumab-achieved-a-pronounced-overall-response-rate-as-a-single-agent-with-tolerable-safety-profile-in-heavily-pre-treated-multiple-myeloma-patients>
DMC recommends termination of study into daratumumab with atezolizumab to treat NSCLC，European Pharmaceutic Manufacturer[online](retrieved on 2020 Jul 26)，2018年05月30日，retreived from the Internet<URL:https://www.epmmagazine.com/news/dmc-recommends-termination-of-study-into-daratumumab/>

Also Published As

Publication number Publication date
EP3313441A1 (en) 2018-05-02
CL2017003275A1 (es) 2018-04-20
MA71262A (fr) 2025-04-30
PL3313441T3 (pl) 2024-08-19
KR20240150522A (ko) 2024-10-15
PH12017502311A1 (en) 2018-06-25
FI3313441T3 (fi) 2024-03-28
NZ777474A (en) 2025-05-02
HRP20240338T1 (hr) 2024-05-24
LT3313441T (lt) 2024-05-27
SV2017005607A (es) 2019-03-28
EP4385569A2 (en) 2024-06-19
JP2018527299A (ja) 2018-09-20
EP4385569A3 (en) 2024-09-25
ECSP17084878A (es) 2018-02-28
CA2990620A1 (en) 2016-12-29
MY193727A (en) 2022-10-27
KR102713847B1 (ko) 2024-10-04
CN107921120A (zh) 2018-04-17
HK1254942A1 (en) 2019-08-02
ZA201800476B (en) 2021-05-26
PE20181090A1 (es) 2018-07-09
PT3313441T (pt) 2024-05-07
EP3313441A4 (en) 2019-04-24
RS65347B1 (sr) 2024-04-30
MX2021012133A (es) 2021-11-03
EP3313441B1 (en) 2024-02-21
SMT202400127T1 (it) 2024-05-14
AU2016281717A1 (en) 2018-01-18
MX2021012134A (es) 2021-11-03
JP2024153803A (ja) 2024-10-29
UA124799C2 (uk) 2021-11-24
NZ738206A (en) 2025-05-02
HUE066300T2 (hu) 2024-07-28
DK3313441T5 (da) 2024-10-07
KR20180012864A (ko) 2018-02-06
BR112017027990A2 (pt) 2018-08-28
CL2019003657A1 (es) 2020-05-08
IL256248A (en) 2018-02-28
MD3313441T2 (ro) 2024-08-31
GT201700286A (es) 2019-08-08
JP2022070892A (ja) 2022-05-13
SI3313441T1 (sl) 2024-05-31
AU2016281717B2 (en) 2022-07-28
ES2982292T3 (es) 2024-10-15
EA201890131A1 (ru) 2018-05-31
JP7532428B2 (ja) 2024-08-13
DOP2017000305A (es) 2018-04-15
CO2017013332A2 (es) 2018-05-21
WO2016210223A1 (en) 2016-12-29
EA037548B1 (ru) 2021-04-12
MX2018000261A (es) 2018-03-08
US20160376373A1 (en) 2016-12-29
NI201700170A (es) 2019-05-10
DK3313441T3 (da) 2024-04-15

Similar Documents

Publication Publication Date Title
JP7532428B2 (ja) Ｃｄ３８を特異的に結合する抗体による免疫調節及び固形腫瘍の治療
US20250066501A1 (en) Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
KR102384845B1 (ko) 항-pd-l1 항체 및 그의 용도
CN112672760B (zh) 新颖lilrb4抗体和其用途
CN107530428B (zh) Icos的抗体
TWI751397B (zh) 抗 lag-3 抗體及其用途
JP2021501606A (ja) Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
HK1258249A1 (zh) 用於测定icos表达的基因标志
WO2022120064A1 (en) Methods for identifying lilrb-blocking antibodies
KR20240049794A (ko) Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도
TWI742008B (zh) 使用特異性結合ｃｄ３８之抗體免疫調節及治療固態腫瘤
EP4247497A1 (en) Anti-cd25 antibodies
HK40111835A (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
HK1254942B (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
HK1254148A1 (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
BR122025009440A2 (pt) Usos de um anticorpo que se liga especificamente a cd38

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220311

R150 Certificate of patent or registration of utility model

Ref document number: 7041519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250